Capital and Coast District Health Board logo

FINCH 1

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

This study is currently recruiting participants.

Trial website: https://clinicaltrials.gov/ct2/show/NCT02889796?term=rheumatoid+arthritis+filgotinib&rank=4 

Trial purpose: The primary objective of this study is to evaluate the effects of filgotinib versus placebo in adults with active rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX).

FINCH 3

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

Trial website: https://clinicaltrials.gov/ct2/show/NCT02886728?term=rheumatoid+arthritis+filgotinib&rank=3 

Trial purpose: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy

Sirukumab for giant cell arteritis

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Phone: Marina Dzhelali on 04 918 5117

Email: Marina.Dzhelali@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/ct2/show/NCT02531633

Trial purpose: Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis (GCA) by interruption of multiple pathogenic pathways. Sirukumab inhibits IL-6-mediated signal transducer and activator of transcription 3 (STAT3) phosphorylation, resulting in the inhibition of the biological effect of IL-6. This study will evaluate the efficacy and safety of sirukumab to characterize the benefit-to-risk profile of sirukumab in the treatment of active GCA. The study will be conducted in 2 distinct parts (Part A and Part B) and consists of the following phases: Screening phase, Part A: 52-week double-blind treatment phase, Part B: 104-week extension phase with the option to receive open-label sirukumab based on disease status and a 16-week follow-up phase if applicable.

Last updated 24 August 2017.